In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients ( n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection ( n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection ( n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose. Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals.
All Keywords
【저자키워드】 antibodies, SARS-CoV-2, viral infection, RNA vaccines, 【초록키워드】 Vaccine, BNT162b2 vaccine, antibody, mRNA vaccine, SARS-COV-2 infection, Infection, Symptom, BNT162b2, Cohort, IgG antibody, response, group, single dose, binding, dose, second dose, first dose, individual, recipient, Pfizer–BioNTech, spike-specific IgG, single vaccine, ACE2 antibody, individuals, the vaccine, elicited, infected with SARS-CoV-2, of BNT162b2, 【제목키워드】 Antibody Response, BNT162b2 mRNA vaccine, individual, infected with SARS-CoV-2,
【저자키워드】 antibodies, SARS-CoV-2, viral infection, RNA vaccines, 【초록키워드】 Vaccine, BNT162b2 vaccine, antibody, mRNA vaccine, SARS-COV-2 infection, Infection, Symptom, BNT162b2, Cohort, IgG antibody, response, group, single dose, binding, dose, second dose, first dose, individual, recipient, Pfizer–BioNTech, spike-specific IgG, single vaccine, ACE2 antibody, individuals, the vaccine, elicited, infected with SARS-CoV-2, of BNT162b2, 【제목키워드】 Antibody Response, BNT162b2 mRNA vaccine, individual, infected with SARS-CoV-2,
BNT162b2(Pfizer-BioNTech) mRNA 백신 수혜자 코호트(n = 1,090)에서, 우리는 SARS-CoV-2 감염이 있었던 개인에서 단일 백신 용량에 의해 스파이크 특이적 IgG 항체 수준과 ACE2 항체 결합 억제 반응이 유발되었음을 관찰했습니다. ( n = 35) 이전에 감염되지 않은 개인에서 2 회 접종 후 나타난 것과 유사했습니다 ( n = 228). 백신 접종 후 증상은 1차 접종 후 이전에 감염이 있었던 사람들에서 더 두드러졌지만 증상은 2차 접종 후 그룹 간에 유사했습니다. 이전에 SARS-CoV-2에 감염된 개인에서 BNT162b2 백신 1회 접종 후 바이러스 특이적 항체 수준은 감염 경험이 없는 개인에서 2회 백신 접종 후 수준과 유사합니다.